The cost-effectiveness of human papillomavirus vaccination in the Philippines.
Vaccine
; 40(27): 3802-3811, 2022 06 15.
Article
en En
| MEDLINE
| ID: mdl-35606237
ABSTRACT
Cervical cancer is the second most common cancer among women in the Philippines. Human papillomavirus (HPV) vaccination provides protection from the most common cancer-causing HPV types. This analysis used a proportionate outcomes model to estimate the potential cost-effectiveness of four different HPV vaccine products-Cervarix™, Cecolin®, GARDASIL®, and GARDASIL®9-for routine HPV vaccination of 10 cohorts of 9-year-old girls from the government and societal perspectives. Model parameters included cervical cancer burden, healthcare and program costs, vaccine efficacy with and without potential cross-protection, and vaccination coverage. Univariate and probabilistic sensitivity analyses evaluated the impact of uncertainty on model results. Compared to no vaccination, HPV programs with Cecolin®, Cervarix™, and GARDASIL® are projected to be cost-effective at US$1,210, US$1,300, and US$2,043 per DALY averted, respectively, from the government perspective, and at US$173, US$263, and US$1,006 per DALY averted, respectively, from the societal perspective when cross-protection was considered. When direct comparisons were made across vaccines, GARDASIL® was dominated by Cervarix™ and Cecolin®. In a scenario where cross-protection was not considered, results were similar except that Cervarix™ and GARDASIL® were both dominated by Cecolin®. GARDASIL®9 was not cost-effective under any of the modeled scenarios.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias del Cuello Uterino
/
Infecciones por Papillomavirus
/
Alphapapillomavirus
/
Vacunas contra Papillomavirus
Tipo de estudio:
Health_economic_evaluation
Límite:
Child
/
Female
/
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Vaccine
Año:
2022
Tipo del documento:
Article
País de afiliación:
Filipinas